Delafloxacin
Tier C — Watch / tradeDelafloxacin · all drugs expiring in 2029 →
Targets：Topoisomerase IV, Bacterial DNA gyrase
Brand：Baxdela, Quofenix
Indications (approved)：Community-acquired bacterial pneumonia, Community-acquired pneumonia, Bacterial skin disease, Skin and skin structure infection
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| DELAF-001 | 446-17-3 | 2,4,5-trifluorobenzoic acid |
| DELAF-002 | 98349-24-7 | ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate |
| DELAF-003 | 247069-27-8Available | 3,5-difluoropyridine-2,6-diamine |
| DELAF-004 | 875712-88-2 | (Z)-ethyl 3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)acrylate |
| DELAF-005 | 18621-18-6 | azetidin-3-ol hydrochloride |
| DELAF-006 | - | ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate |
| Code | CAS No. | Intermediate |
|---|---|---|
| DELAF-003 | 247069-27-8Available | 3,5-difluoropyridine-2,6-diamine |
| DELAF-005 | 18621-18-6 | azetidin-3-ol hydrochloride |
| DELAF-007 | 101987-86-4Available | ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate |
| DELAF-008 | 101987-87-5Available | (Z)-ethyl 2-(3-chloro-2,4,5-trifluorobenzoyl)-3-ethoxyacrylate |
| DELAF-009 | 339591-73-0 | (Z)-ethyl 3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(3-chloro-2,4,5-trifluorobenzoyl)acrylate |
| DELAF-010 | - | ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate |
| DELAF-011 | - | ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate |
| DELAF-012 | - | sodium 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate |
Frequently asked questions
What are the approved indications of Delafloxacin?
Approved indications include: Community-acquired bacterial pneumonia, Community-acquired pneumonia, Bacterial skin disease, Skin and skin structure infection.
When does the Delafloxacin patent expire?
Based on public sources, the Delafloxacin patent expires in 2029.
How many synthesis routes are recorded for Delafloxacin?
2 synthesis routes are recorded; the shortest is 4 steps with 73 kg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Delafloxacin intermediates?
3 intermediate CAS of Delafloxacin are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Delafloxacin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29